Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On March31, 2017, upon the recommendation of the Nominating and
Corporate Governance Committee of the Board of Directors (the
Board) of Alder BioPharmaceuticals,
Inc. (the Company), the Board appointed
Wendy Yarno to serve as a Class II director of the Company until
the Companys 2019 Annual Meeting of Stockholders and until her
successor has been duly elected and qualified, or until her
earlier death, resignation or removal.
As a non-employee director, Ms.Yarno is entitled to receive a
$40,000 annual retainer for her service on the Board and may
receive additional cash amounts for service on any committees of
the Board. In addition, Ms.Yarno is entitled to receive an option
to purchase a total of 30,000 shares of the Companys common
stock, vesting on a three-year annual vesting schedule, provided
she continues to serve as a Board member through each such
vesting date, provided, further that such option will vest in
full upon a change in control of the Company. The 2014 Equity
Incentive Plan and the form of option agreement under the 2014
Equity Incentive Plan were filed as Exhibits 10.4 and 10.5,
respectively, to our Form S-1 (File No.333-194672) filed with the
Securities and Exchange Commission on April25, 2014.
| Item7.01 | Regulation FD |
A copy of the press release issued in connection with Ms.Yarnos
appointment is furnished with this Form 8-K and attached hereto
as Exhibit 99.1.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 | Press Release, dated April 4, 2017 |
About Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company’s pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company’s monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone, and is being developed for the treatment of Cushing’s disease. Its candidate, Eptinezumab, is an investigational product candidate being developed as a migraine prevention treatment for patients with chronic and frequent episodic migraine. It is also is developing ALD1910, a genetically engineered monoclonal antibody. Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Recent Trading Information
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) closed its last trading session down -0.50 at 19.70 with 600,041 shares trading hands.
